National Pension Service Purchases 706 Shares of Axon Enterprise, Inc $AXON

Key Points

• The National Pension Service increased its stake in Axon Enterprise, Inc by 0.8%, owning 88,306 shares valued at $46.45 million as of the end of the first quarter.
• Several institutional investors have also raised their holdings in Axon, with ownership among institutional investors reaching 79.08% of the company’s stock.
• Axon Enterprise reported earnings per share of $2.12 for the last quarter, surpassing estimates of $1.54, and achieved a revenue increase of 32.6% year-over-year.

National Pension Service raised its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 0.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,306 shares of the biotechnology company's stock after buying an additional 706 shares during the quarter. National Pension Service owned 0.11% of Axon Enterprise worth $46,445,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of AXON. Capital World Investors grew its stake in shares of Axon Enterprise by 86.4% during the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after buying an additional 841,772 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Axon Enterprise by 58,725.5% during the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after purchasing an additional 763,431 shares during the period. Jennison Associates LLC lifted its holdings in shares of Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock valued at $322,961,000 after purchasing an additional 611,418 shares in the last quarter. Nuveen LLC purchased a new position in Axon Enterprise during the first quarter worth about $264,796,000. Finally, Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after buying an additional 212,931 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Trading Down 3.6%

NASDAQ:AXON traded down $28.68 during trading hours on Tuesday, hitting $762.94. The company had a trading volume of 246,547 shares, compared to its average volume of 709,543. The stock has a 50-day moving average price of $774.01 and a 200 day moving average price of $671.39. The company has a market capitalization of $59.89 billion, a PE ratio of 188.38, a price-to-earnings-growth ratio of 27.68 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a 52 week low of $346.71 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million for the quarter, compared to analysts' expectations of $641.77 million. During the same period in the prior year, the firm earned $1.20 earnings per share. The firm's revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In other news, Director Michael Garnreiter sold 5,913 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the completion of the sale, the director owned 17,740 shares of the company's stock, valued at $13,482,400. The trade was a 25.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CRO Cameron Brooks sold 3,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the sale, the executive owned 19,447 shares of the company's stock, valued at $14,405,559.72. This trade represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 53,695 shares of company stock valued at $40,964,638 over the last quarter. 4.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Craig Hallum raised Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target on the stock in a research report on Tuesday, August 5th. The Goldman Sachs Group increased their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Northland Securities set a $800.00 price objective on Axon Enterprise in a research note on Tuesday, August 5th. UBS Group restated a "neutral" rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the company an "overweight" rating in a research report on Friday, July 11th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $837.69.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.